comparemela.com

Latest Breaking News On - Reimbursement drug list - Page 9 : comparemela.com

Live from ASCO 2023 | Ascentage Pharma Releases the First Dataset of Lisaftoclax in WM, Revealing Encouraging Therapeutic Potential

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

Hong kongWestern australiaUnited statesPrnewswire ascentage pharmaSikander ailamadhiYifan zhaiAscentage pharmaAmerican society of clinical oncologyChina national medical products administrationNational reimbursement drug listDana farber cancer instituteMd anderson cancer centerMajor nationalPoster presentationAmerican societyClinical oncology

Live from ASCO 2023 | Ascentage Pharma Releases Updated Data Showing APG-2449 s Potential as a New Treatment for Drug-Resistant NSCLC

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

United statesLi zhangWestern australiaHong kongYifan zhaiAscentage pharmaNational reimbursement drug listAmerican society of clinical oncologySun yat sen university cancer centerChina national medical products administrationMajor nationalMd anderson cancer centerDana farber cancer institutePoster discussionAmerican societyClinical oncology

American Society of Clinical Oncology confers highest honor upon Prof Hagop Kantarjian

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),.

United statesHong kongHagopm kantarjianAscentage pharmaDajun yangDavida karnofskyDana farber cancer instituteMd anderson cancer centerAmerican society of clinical oncologySamsung distinguished universityDepartment of leukemiaRice baker institute houstonSociety of hematologic oncologyUniversity of texas md anderson cancer centerMajor nationalNational reimbursement drug list

Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93 8% Signals a Potential Clinical Breakthrough

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

Hong kongUnited statesWestern australiaInnovent biologicsRuihua xuYifan zhaiAscentage pharmaAmerican society of clinical oncologyMd anderson cancer centerMajor nationalEuropean unionDana farber cancer instituteSun yat sen university cancer centerEuropean medicines agencyAmerican society of hematologyChina national medical products administration

Live from ASCO 2023 | For the Third Consecutive Year, Ascentage Pharma Releases Promising Results of Alrizomadlin plus Pembrolizumab in Patients with Cutaneous Melanoma that Failed Immuno-Oncologic (IO) Therapies

SUZHOU, China, and ROCKVILLE, Md., June 5, 2023 /PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated results from a Phase II study of MDM2-P53 inhibitor, alrizomadlin (APG-115), in combination with pembrolizumab in patients with unresectable or.

United statesSan antonioUniversity of texasWestern australiaHong kongAscentage pharmaYifan zhaiPrnewswire ascentage pharmaMontaserf shaheenMd anderson cancer centerMajor nationalDana farber cancer instituteChina national medical products administrationUniversity of texas health science centerAmerican society of clinical oncologyNational reimbursement drug list

vimarsana © 2020. All Rights Reserved.